These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32358591)

  • 21. Raising the bar for market authorisation of new drugs.
    Naci H; Cylus J; Vandoros S; Sato A; Perampaladas K
    BMJ; 2012 Aug; 345():e4261. PubMed ID: 22872693
    [No Abstract]   [Full Text] [Related]  

  • 22. Introduction and commentary: Paving the way for biosimilars in oncology, part 3: Clinical and economic impact of oncology biosimilars.
    Abraham J
    Semin Oncol; 2014 Apr; 41 Suppl 3():S1-2. PubMed ID: 24767631
    [No Abstract]   [Full Text] [Related]  

  • 23. Prescription drugs marketed in the United States should be approved by the FDA.
    Shepherd MD; Curtiss FR
    J Manag Care Pharm; 2003; 9(4):366-7. PubMed ID: 14613456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sandoz sues FDA over delay in first biogeneric approval.
    Fox JL
    Nat Biotechnol; 2005 Nov; 23(11):1327-8. PubMed ID: 16273046
    [No Abstract]   [Full Text] [Related]  

  • 25. Frontiers in nonclinical drug development: biosimilars.
    Ryan AM
    Vet Pathol; 2015 Mar; 52(2):419-26. PubMed ID: 25161206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Why Are Biosimilars Not Living up to Their Promise in the US?
    Zhai MZ; Sarpatwari A; Kesselheim AS
    AMA J Ethics; 2019 Aug; 21(8):E668-678. PubMed ID: 31397662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Obstacles to the Adoption of Biosimilars for Chronic Diseases.
    Hakim A; Ross JS
    JAMA; 2017 Jun; 317(21):2163-2164. PubMed ID: 28459924
    [No Abstract]   [Full Text] [Related]  

  • 28. FDA's Gottlieb Aims To End Biosimilars Groundhog Day.
    Kirkner RM
    Manag Care; 2019 Jan; 28(1):5-6. PubMed ID: 30883313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale, Opportunities, and Reality of Biosimilar Medications.
    Lyman GH; Zon R; Harvey RD; Schilsky RL
    N Engl J Med; 2018 May; 378(21):2036-2044. PubMed ID: 29791832
    [No Abstract]   [Full Text] [Related]  

  • 30. Biosimilar Makers Hope Court Starts 6-Month Wait Sooner.
    Silverman E
    Manag Care; 2017 Mar; 26(3):31. PubMed ID: 28510518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Competition in the Age of Biosimilars.
    Chandra A; Vanderpuye-Orgle J
    JAMA; 2015 Jul; 314(3):225-6. PubMed ID: 26197179
    [No Abstract]   [Full Text] [Related]  

  • 32. Trends in boxed warnings and withdrawals for novel therapeutic drugs, 1996 through 2012.
    Cheng CM; Shin J; Guglielmo BJ
    JAMA Intern Med; 2014 Oct; 174(10):1704-5. PubMed ID: 25127107
    [No Abstract]   [Full Text] [Related]  

  • 33. Biosimilars Ready, At Last, To Make Their Entrance: Stars Are Born or Do They Fizzle?
    Reinke T
    Manag Care; 2017 Mar; 26(3):20-23. PubMed ID: 28510515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biopharmaceutical benchmarks 2018.
    Walsh G
    Nat Biotechnol; 2018 Dec; 36(12):1136-1145. PubMed ID: 30520869
    [No Abstract]   [Full Text] [Related]  

  • 35. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK
    Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
    [No Abstract]   [Full Text] [Related]  

  • 36. Examining Manufacturing Readiness for Breakthrough Drug Development.
    Dye E; Sturgess A; Maheshwari G; May K; Ruegger C; Ramesh U; Tan H; Cockerill K; Groskoph J; Lacana E; Lee S; Miksinski SP
    AAPS PharmSciTech; 2016 Jun; 17(3):529-38. PubMed ID: 26608693
    [No Abstract]   [Full Text] [Related]  

  • 37. Biosimilars for Rheumatoid Arthritis: Don't Count Them Out Quite Yet.
    Rychlick N
    Manag Care; 2018 Jan; 27(1):29. PubMed ID: 29369768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Tortoise and the Hare: Evolving Regulatory Landscapes for Biosimilars.
    Konara CS; Barnard RT; Hine D; Siegel E; Ferro V
    Trends Biotechnol; 2016 Jan; 34(1):70-83. PubMed ID: 26620970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biosimilars: An Approach to some Current Worldwide Regulation Frameworks.
    Esteban E; Bustos RH; García JC; Jáuregui E
    Curr Clin Pharmacol; 2019; 14(1):16-40. PubMed ID: 30360724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulatory considerations in biosimilars: Asia pacific regions.
    Rathore AS; Bhargava A
    Prep Biochem Biotechnol; 2021; 51(1):1-8. PubMed ID: 32921222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.